Drug Profile
PLG 0206
Alternative Names: Antimicrobial peptides - Peptilogics; eCAPS - Peptilogics; engineered Cationic Antimicrobial Peptides - Peptilogics; PLG-0206Latest Information Update: 21 Sep 2023
Price :
$50
*
At a glance
- Originator Peptilogics
- Class Anti-infectives; Antibacterials; Antimicrobial cationic peptides
- Mechanism of Action Bacterial biofilm inhibitors; Cell membrane permeability enhancers; Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bone and joint infections
- No development reported Bacterial infections
Most Recent Events
- 21 Sep 2023 Efficacy data from a phase I trial in Bone and joint infections released by Peptilogics
- 24 May 2023 Interim adverse events data from a phase Ib trial in Bone and Joint Infection released by Peptilogics
- 28 Apr 2023 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)